Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study-Reference-Cited by-同舟云学术

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Published:2017-05-12 Issue:11 Volume:31 Page:2443-2448
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kumar S K^ORCID,Dimopoulos M A,Kastritis E,Terpos E,Nahi H,Goldschmidt H,Hillengass J,Leleu X,Beksac M^ORCID,Alsina M,Oriol A,Cavo M,Ocio E M,Mateos M V,O'Donnell E K,Vij R,Lokhorst H M,van de Donk N W C J,Min C,Mark T,Turesson I,Hansson M^ORCID,Ludwig H,Jagannath S,Delforge M,Kyriakou C,Hari P,Mellqvist U,Usmani S Z,Dytfeld D,Badros A Z,Moreau P,Kim K^ORCID,Otero P R,Lee J H,Shustik C,Waller D,Chng W J,Ozaki S,Lee J-J,de la Rubia J,Eom H S,Rosinol L,Lahuerta J J,Sureda A,Kim J S,Durie B G M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu2017138.pdf

Reference20 articles.

1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–1128.

2. Pulte D, Jansen L, Castro FA, Emrich K, Katalinic A, Holleczek B et al. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. Br J Haematol 2015; 171: 189–196.

3. Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H et al. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J 2015; 5: e349.

4. Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J 2016; 6: e401.

5. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467–472.

Cited by 273 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: Applications in PET imaging of multiple myeloma;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-11

2. Influence of lithium ion doping and mitoxantrone hydrochloride loading on the structure and in vitro biological properties of mesoporous bioactive glass microspheres in the treatment of multiple myeloma;Colloids and Surfaces A: Physicochemical and Engineering Aspects;2024-08

3. Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-08

4. Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA;The Lancet Haematology;2024-07

5. A research center’s experience of T-cell–redirecting therapies in triple-class refractory multiple myeloma;Blood Advances;2024-06-28